Molecular Name | Target point | Molecular model | Indication | Development stage |
Catumaxomab [15] {!!! INVALID CITATION !!! , #0;Knodler, 2018 #10} {!!! INVALID CITATION !!! , #0;Knodler, 2018 #11} | EPCAM + CD3 | TrioMab | Malignant ascites | Approved |
MT110 [16] | EPCAM + CD3 | BiTE | Colorectal cancer | Phase I |
Blinatumomab [17] | CD19 + CD3 | BiTE | Acute myeloid leukemia | Approved |
MT111 [18] | CEA + CD3 | BiTE | Gastric adenocarcinoma | Phase I |
MGD006 [19] | CD123 + CD3 | DART | Acute myeloid leukemia | Phase I |
MGD007 [20] | GPA33 + CD3 | DART | colorectal cancer | Phase I |
AFM11 [21] | CD3 + CD19 | TandAb | Non-Hodgkin’s lymphoma | Phase I |
AFM13 [22] | CD30 + CD16 | TandAb | Hodgkin’s lymphoma | Phase I |
RG7221 | Ang-2 + VEF | CrossMab | colorectal cancer | Phase II |
RG7802 [23] | CEA + CD3 | CrossMab | Solid tumor | Phase I |